- 1 Title: COVID-19 in Latin America: Contrasting phylodynamic inference with
- 2 epidemiological surveillance.
- 3 Running title: Phylodynamic analysis of COVID-19 in Latin America
- 4 Authors: Diana M. Rojas-Gallardo, Sandra C. Garzón-Castaño, (https://orcid.org/0000-0002-9547-
- 5 967X), Natalia Millán², Erika V. Jiménez-Posada^{4, (http://orcid.org/0000-0002-3737-9427)}, Jaime A.
- 6 Cardona-Ospina. 1,2,3,4* (https://orcid.org/0000-0003-3996-2293)
- 7 Affiliations: ¹Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación
- 8 Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. ²Semillero de
- 9 Investigación en Infecciones Emergentes y Medicina Tropical, SIEM, Fundación
- 10 Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia, ³Public Health and
- 11 Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira,
- 12 Pereira, Risaralda, Colombia. ⁴Emerging Infectious Diseases and Tropical Medicine
- Research Group. Instituto para la Investigación en Ciencias Biomédicas Sci-Help, Pereira,
- 14 Risaralda, Colombia. Grupo de Biotecnología-Productos Naturales, Facultad de Tecnología,
- 15 Universidad Tecnológica de Pereira, Colombia
- *Corresponding author: Jaime A. Cardona-Ospina, Phone +57 311 339 5249, Fundación
- 17 Universitaria Autónoma de las Américas, Bloque B, Av. de las Américas #98-56 Sector
- 18 Belmonte, Pereira, Risaralda, Colombia, Postal Code: 660001, e-mail:
- 19 jaime.cardona@uam.edu.co

20 Words: 1991 | Abstract: 308 | Figures: 3 | Tables: 1 | Supplementary Tables: 2

Abstract:

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Introduction: SARS-CoV-2 infection has represented the one of the largest challenges for humanity. This virus was first detected in Latin America and the Caribbean (LAC) in Brazil in February 26, 2020 and it has revealed important gaps in infectious disease surveillance that must be covered. Phylodynamic analysis is a tool that can help to monitor and adapt traditional surveillance measures in order to cover those. Therefore, this work aims to contrast data driven from epidemiologic surveillance in LAC with parameters inferred from phylodynamic analysis of reported genomes of SARS-CoV-2 across different LAC countries Methods: We obtained epidemiological data from daily reports provided by European Centre for Disease Prevention and Control up to 13th May, 2020. We estimated Effective Reproductive Number (Re) and calculated epidemic curves with exponential growth (EG) and maximum likelihood (ML) methods. SARS-CoV-2 phylodynamic in Latin-American was analyzed using sequences reported in GISAID for Central and South America up to May 13th 2020. Sequences were aligned, and ML phylogeny was constructed. Coalescent model Birth Death SIR (serial) was run, and SIR trajectories from the birth-death SIR model were plotted. **Results:** A total of 404,448 cases were reported up to 13th May 2020. Overall reproduction number for Latin America, estimated through the EG and ML methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311) respectively. Phylodynamic analysis for Latin America showed an overall Re of 1.27 (IC95% 1.07 to 1.49). We did not find statistically significant differences between epidemiological and phylodynamic data at the cut-off time, except for Brazil. **Discussion:** Our results support that epidemiological and genomic surveillance are two complementary approaches. Evidence suggests that even with a low number of sequences proper estimations of Re could be performed. We suggest that countries, especially developing

- 46 countries, should consider to add genomic surveillance to their systems for monitoring and
- 47 adapting epidemiological surveillance of SARS-CoV-2.
- 49 Keywords:

51

50 SARS-CoV-2, COVID-19, Phylodynamic, Epidemiology, Latin America

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Introduction: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus - 2) infection, called COVID-19, has represented one of the largest challenge for humanity, and has revealed the need for better, more accurate, and more expedite surveillance tools, for improving infectious disease control. SARS-CoV-2 transmissibility across the world has varied widely¹, apparently related with control measures, and intensity of disease surveillance. COVID-19 has revealed deep gaps in our society derived from social inequalities, and has showed the importance of solid evidence based decision making, the need to strength our healthcare systems and to improve infectious disease surveillance. After the emergence of SARS-CoV-2 in Wuhan, central China in December 2019, COVID-19 rapidly spread across the world, and was first reported in Latin America and the Caribbean (LAC) on February 26, 2020 in Brazil¹. This virus belongs to the genus Betacoronavirus of the Coronaviridae family, it has a (+) ssRNA genome of approximately 29,903bp, and the genomic information accumulated through its evolution has been used for tracking its molecular relatedness with other coronaviruses, and for estimating transmission networks, epidemic size, and effective reproduction number (Re) ²⁻⁵. In this context, current available phylogenetic methods can serve as tool for improving infectious disease surveillance. Development of the coalescent theory allows to infer from evolutionary analysis the epidemiologic behavior of a pathogen, especial those rapidly evolving, like RNA virus⁶⁻⁸. These analysis can enhance disease surveillance efforts,

provide additional data for adapting disease surveillance strategies, and can help to assess

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

effectiveness of implemented surveillance as well as to estimate the Re, generation time, and epidemic size 9, 10. This work aims to contrast data driven from epidemiologic surveillance in LAC with parameters inferred from phylodynamic analysis of reported genomes of SARS-CoV-2 across different LAC countries. **Materials and Methods** Epidemiological data source In order to contrast phylodynamic inference with COVID-19 epidemiological surveillance data, we obtained data published by the European Centre for Disease Prevention and Control ¹ until 13th May, 2020. Countries were filtered by continent and only countries belonging to Latin America and the Caribbean region were included. Incident cases and dates of reporting were obtained, as well as fatal cases. We calculated Case Fatality Rates (CFR) = number of reported deaths/number of total cases) X 100, and estimated Re and epidemiologic curves using exponential growth and maximum likelihood methods¹¹⁻¹³. **Estimation of Effective Reproduction Numbers** In order to estimate Re, we estimated the Generation time (GT) using the R package R0 ¹¹. The distribution of the generation time, considered as the time between a primary infected case and a secondary case, was estimated by Maximun Likelihood using the serial time between infectee/infector pairs published by He et al, 2020 11, 14. Then, Re at the beginning of the epidemic, and its evolution through time were estimated using Exponential Growth

(EG) and Maximum Likelihood (ML) methods ^{12, 13, 15}. The time period over which growth is exponential was estimated using the deviance R-squared statistic over a range of possible time periods ¹¹.

Dataset for phylodynamic analysis

In order to investigate de SARS-CoV-2 phylodynamic in Latin-American, we search for sequences reported in GISAID ¹⁶ for Central and South America up to May 13th 2020. We choose only whole genome sequences (>29,900) of the virus with high coverage, and more than 95% of nucleotide base resolved. We conserved identical sequences with different sampling dates and different location and discard identical sequences with same sampling date between countries. Accession IDs, sampling dates and locations of the sequences were obtained, as well as clinical metadata when available. We also generated subgroup datasets for each country reporting at least five sequences.

Phylogenetic analyses

Sequences were aligned using MAFFT software v7.450 ¹⁷ and visually inspected and edited using Bioedit v7.0.5.3. To assess the recombination for the dataset, we employed the pairwise homoplasy index (PHI) test using SplitsTree v4.15.1¹⁸. Nucleotide substitution model for the alignment was inferred according to the corrected Akaike information criterion (AICc) in jModelTest v2.1.10 ¹⁹. Maximun Likelihood (ML) phylogeny was constructed using PhyML software v3.1²⁰ and the tree was visualized and edited with FigTree software v1.8.

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Coalescent analyses For LAC and each country data set, coalescent model Birth Death SIR (serial) ²¹ was run with *Phylodynamics* package in BEAST v2.6.2.0 ²². Priors were introduced with BEAUti and all data sets were run with the same prior distribution and value for Molecular clock rate (1.0 (estimated)), Become Uninfectious Rate (Normal (mean=37.0, sigma =1.3)) and Reproductive Number (Log-normal (mean log=0,0, sd log =1.2)). Markov chain Monte Carlo (MCMC) runs of 80 million states sampling every 8,000 steps were computed. The convergence of MCMC chains was checked using Tracer v.1.7.1²³, ensuring that the effective sample size (ESS) values were greater than 300 for each parameter estimated. For LAC data set, the maximum clade credibility (MCC) trees were obtained from the tree posterior distribution using TreeAnnotator after 10% burn-in ²³. To plot SIR trajectories from the birth-death SIR model we used NELSI package for R. Sensitivity analysis We conducted a sensitivity analysis computing the R-squared statistic over a range of possible time periods for exponential growth (begin between days 1 to 39, and ending between days 40 to 79), selecting the best fit for EG and ML analysis. In order to assess the effect of GT distribution variation on Re estimation, we computed the reproduction ratio over a range of chosen generation time distributions with mean between 1 to 14 days, assuming fixed standard deviation, and using ML method.

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Results A total of 404,448 cases were reported up to 13th May 2020, with 23,153 deaths (overall CFR 5.72%). The countries with most cases were: Brazil (177,589 cases), Peru (72,059 cases), Mexico (38,324 cases), Chile (31,721 cases) and Ecuador (30,419 cases), while the countries with the highest CFR were Saint Maarteen (19.48%), British Virgin Islands (14.29%), Antigua and Barbuda (12%), Bahamas (11.83%) and Belize (11.11%), Table 1. A total of 124 genomic sequences were retrieved from GISAID library ¹⁶, and after quality clearance 76 genomic sequences, from 6 countries, were finally included for analysis (Supplementary Table 1). Overall reproduction number for Latin America, estimated through the EG and ML methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311) respectively. The epidemic curve and time dependent analysis is showed in Figure 1. The portion of the epidemic curve that best fitted exponential growth was estimated between 2020-02-26 and 2020-04-11 (first 45 days), with a Growth Rate of 11.91%, and a Re of 1.95 (IC95% 1.94 to 1.95) and 1.74351(IC95% 1.72 to 1.77) through EG and ML method, respectively. Sensitivity analysis showed that Re remained within the 95%IC only for a small choice of time windows Figure 1c, and that varied significantly across different GT distributions (data not shown). For Latin American ML phylogenetic reconstruction, the GTR+I+G was the best model of nucleotide substitution for the data set (substitution rates for every data set is showed in Supplementary Table 2). The PHI test did not found statistically significant evidence for

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

recombination (p = 0.01381). The ML tree (Figure 2) shown a star-like topology in which the external arms are longer than the internal without evidence of structure or space related distribution. Phylodynamic analysis for Latin America showed an overall Re of 1.27 (IC95% 1.07 to 1.49). To properly contrast observed epidemiologic curves with phylodynamic inferences, we performed subgroup analysis including only countries with at least five reported genomic sequences, and estimating epidemiological observed Re up to the date of the last available genomic sequence. Therefore, only four countries were finally included in the subgroup analysis; Brazil (last reported sequence 03-26-2020, 30 days since first case notification), Argentina (last reported sequence 04-19-2020, 44 days since first case notification), Chile (last reported sequence 03-08-2020, 5 days after first case notification) and Costa Rica (last reported sequence 03-25-2020, 18 days after first case notification). Epidemic curves and SIR trajectories for each country are showed in Figure 3. Posterior summary of epidemiological and evolutionary parameters are shown in Table 1. When contrasting observed and inferred Re, we did not find statistically significant differences between epidemiological and phylodynamic data at the cut-off time, except for Brazil. Phylodynamic inference showed an Re for Argentina of 1.48 (IC95% 1.19 to 1.79) contrasted with epidemiological Re estimated using EG of 1.39 (IC95%1.36 to 1.41) and ML of 1.29 (IC95% 1.22 to 1.36). For Brazil showed a Re of 1.59 (IC95% 1.18 to 2.03) contrasted with epidemiological Re estimated using EG of 3.03 (IC95% 2.92 to 3.15) and ML of 2.51 (IC95% 2.37 to 2.65). For Costa Rica showed an Re of 2.33 (IC95% 1.02 to 3.78) contrasted with epidemiological Re estimated using EG of 2.14 (IC95% 1.84 to 2.48)

and ML of 2.09 (IC95% 1.69 to 2.56). And for Chile showed 2.69 (IC95% 1.15 to 4.41) contrasted with epidemiological Re estimated using EG of 0.02 (IC95% 0.00 to 4.51) and ML of 2.87 (IC95% 0.48 to 8.86). Additionally, we found important differences in the number of reported versus inferred prevalent cases. Phylodynamic analysis showed a total of 119 cases in Brazil, 245 cases in Argentina, 58 in Chile, and 61 cases in Costa Rica, contrasted with a total of 2,433; 2,828; 5; 177 cases reported in each country respectively, at the time of cut-off.

Discussion:

Our results revealed an overall agreement between epidemiological observed data and photodynamically inferred Re, even for Costa Rica with only five reported genomic sequences up to the date of cut off. However, observed and inferred Re for Brazil varied widely among methods. Sensitivity analysis revealed that for obtention of overlapping Re IC95%, GT mean should be between 4.29 and 5.62 (SD range between 4.12 and 7.02), hence suggesting that likely transmission dynamics in this country could be different to those previously reported ¹⁴, while the fact that observed and inferred Re were not different among the other countries supports that transmission dynamics are similar to those reported by He et al, 2020¹⁴.

However, SIR trajectories revealed disagreement in terms of incident cases, total cases and recovered cases. For some countries, recovered cases were higher than incident cases, like for example Argentina and Brazil (Figure 3). We hypothesize that this disagreement could be related with the real origin of the sequences reported from each country and the real date

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

of SARS-CoV-2 introduction. Since most of sequences available when the analysis was performed were reported at the beginning of the epidemic in each country, it is possible that genomic data did not reveal internal transmission networks but external transmission networks from imported cases. This could be supported on the analysis of ML phylogenetic tree, which did not reveal a space related distribution. Moreover, SIR trajectories analysis for some countries inferred recovered cases above infected cases. This disagreement with the observed epidemiological data is interpreted by our group as a likely introduction before the epidemiological reported date. In order to support this hypothesis, we are currently performing Time to Most Recent Ancestor Analysis (TMRA) for each country, including new reported sequences for LAC, which up to May 22, 2020 have increased to 326 (complete and with high coverage). Finally, our results support that epidemiological and genomic surveillance are two complementary approaches for analysis of transmission and epidemiological patterns. Overall Re estimation for LAC through phylodynamic analysis showed good agreement with observed Re through epidemiological surveillance even when sequences were not available from every country. Evidence suggests that even with a low number of sequences, proper estimations of Re could be performed. This could provide important insights, especially at the beginning of an epidemic when epidemiological surveillance systems are adjusting follow-up and control measures. At the same time, we found that the lack of clinical and epidemiological metadata for reported sequences difficult making phylodynamic inferences. We suggest that countries, especially developing countries,

should consider to add genomic surveillance to their systems for monitoring and adapting epidemiological surveillance of SARS-CoV-2.

Acknowledgements:

We would like to acknowledge Grupo de Investigación SIRIUS, Facultad de Ingenierias,
Universidad Tecnológica de Pereira, for providing resources for performing high
performance computational analysis. We also want to acknowledge the laboratories that have contributed publicly available genomes via GISAID in Latin America.

References

252


- 254 1. European Centre for Disease Prevention and Control. Geographic distribution of
- 255 COVID-19 cases worldwide. European Centre for Disease Prevention and Control., 2020.
- 256 2. Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Junior Alcantara
- LC, et al. The global spread of 2019-nCoV: a molecular evolutionary analysis. Pathog Glob
- 258 Health 2020; 114:64-7.
- 259 3. Dellicour S, Durkin K, Hong SL, Vanmechelen B, Martí-Carreras J, Gill MS, et al.
- 260 A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics
- of SARS-CoV-2 lineages. bioRxiv 2020.
- 262 4. Li J, Li Z, Cui X, Wu C. Bayesian phylodynamic inference on the temporal
- evolution and global transmission of SARS-CoV-2. J Infect 2020.
- 5. Scire J, Vaughan TG, Stadler T. Phylodynamic analyses based on 93 genomes.
- 265 2020.
- 266 6. Holmes EC. Evolutionary history and phylogeography of human viruses. Annu Rev
- 267 Microbiol 2008; 62:307-28.
- 268 7. Pybus OG, Rambaut A, Harvey PH. An integrated framework for the inference of
- viral population history from reconstructed genealogies. Genetics 2000; 155:1429-37.
- 270 8. Volz EM, Koelle K, Bedford T. Viral phylodynamics. PLoS Comput Biol 2013;
- 271 9:e1002947.
- 272 9. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, et al. Unifying
- the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303:327-32.

- 274 10. Rife BD, Mavian C, Chen X, Ciccozzi M, Salemi M, Min J, et al. Phylodynamic
- applications in 21(st) century global infectious disease research. Glob Health Res Policy
- 276 2017; 2:13-.
- 277 11. Obadia T, Haneef R, Boelle PY. The R0 package: a toolbox to estimate
- 278 reproduction numbers for epidemic outbreaks. BMC Med Inform Decis Mak 2012; 12:147.
- 279 12. Wallinga J, Lipsitch M. How generation intervals shape the relationship between
- growth rates and reproductive numbers. Proc Biol Sci 2007; 274:599-604.
- 281 13. White LF, Pagano M. A likelihood-based method for real-time estimation of the
- serial interval and reproductive number of an epidemic. Stat Med 2008; 27:2999-3016.
- 283 14. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
- shedding and transmissibility of COVID-19. Nat Med 2020; 26:672-5.
- 285 15. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory
- syndrome reveal similar impacts of control measures. Am J Epidemiol 2004; 160:509-16.
- 287 16. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative
- contribution to global health. Glob Chall 2017; 1:33-46.
- 289 17. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7:
- improvements in performance and usability. Mol Biol Evol 2013; 30:772-80.
- 291 18. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies.
- 292 Mol Biol Evol 2006; 23:254-67.
- 293 19. Darriba D, Taboada GL, Doallo R, Posada D. ¡ModelTest 2: more models, new
- 294 heuristics and parallel computing. Nat Methods 2012; 9:772.
- 295 20. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New
- algorithms and methods to estimate maximum-likelihood phylogenies: assessing the
- 297 performance of PhyML 3.0. Syst Biol 2010; 59:307-21.

- 298 21. Kuhnert D, Stadler T, Vaughan TG, Drummond AJ. Simultaneous reconstruction of
- 299 evolutionary history and epidemiological dynamics from viral sequences with the birth-
- death SIR model. J R Soc Interface 2014; 11:20131106.

- 301 22. Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M,
- Gavryushkina A, et al. BEAST 2.5: An advanced software platform for Bayesian
- evolutionary analysis. PLoS computational biology 2019; 15:e1006650.
- 304 23. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization
- in Bayesian Phylogenetics Using Tracer 1.7. Syst Biol 2018; 67:901-4.

Figure 1. Maximum likelihood phylogenetic relationships between sequences of Latin America data set. Branch lengths estimated as nucleotide substitutions per site.






Figure 2. Epidemic curve (A), Time-dependent analysis of Re (B) in Latin America up to May 13th, 2020, and Sensitivity analysis of exponential growth of epidemic curve (C).

343

Figure 3. SIR trajectories (A), and epidemic curves (B) for countries with at least five reported genomic sequences. The line corresponds to the epidemic curve estimated through ML method and the dots to incident cases up to the date of the last reported sequence.




 Table 1. Posterior summary of epidemiological and evolutionary parameters.

	Molecular clock rate	95% HPD	Become Uninfectious Rate	95% HPD	Reproductive Number	95% HPD
Latin America	0.00014	0.00011-0.00018	36.88	34.38-39.39	1.22	1.0446-1.4156
Argentina	0.00013	0.0006-0.002	36.86	34.25-39.25	1.48	1.022-3.78
Brazil	0.00028	0.00018-0.00038	36.97	43.44-39.50	1.59	1.1792-2.0277
Chile	0.00044	0.00006-0.00094	36.97	34.47-39.57	2.69	1.1455-4.4077
Costa Rica	0.00058	0.00018-0.0010	36.93	34.49-39.58	2.32	1.022-3.78

Supplementary Table 1. Substitution model and parameters used to run each data set with BEAST.

Region/Country	Model	Substitutions rates	Parameters	
Latin America	Model = GTR+I+G	R(a) [AC] = 0.3454 R(b) [AG] = 0.8055 R(c) [AT] = 0.1965 R(d) [CG] = 0.3182 R(e) [CT] = 2.6714 R(f) [GT] = 1.0000	p-inv = 0.8980 gamma category count = 0 Frequencies = empirical	
Argentina	Model = GTR+I	R(a) [AC] = 0.0100 R(b) [AG] = 1.4896 R(c) [AT] = 0.0829 R(d) [CG] = 0.4389 R(e) [CT] = 3.9014 R(f) [GT] = 1.0000	p-inv = 0.7800 gamma category count = 0 Frequencies = empirical	
Brazil	Model = GTR+I+G	R(a) [AC] = 0.5540 R(b) [AG] = 0.7814 R(c) [AT] = 0.2557 R(d) [CG] = 0.4662 R(e) [CT] = 2.6314 R(f) [GT] = 1.0000	p-inv = 0.9540 gamma category count = 0 Frequencies = empirical	
Chile	GTR	R(a) [AC] = 0.0216 R(b) [AG] = 0.9991 R(c) [AT] = 0.2091 R(d) [CG] = 0.5565 R(e) [CT] = 3.7915 R(f) [GT] = 1.0000	p-inv = 0.0 gamma category count = 0 Frequencies = empirical	
Costa Rica HKY		Estimate	kappa = estimate	

Supplementary Table 2. Genomic sequences with dates, countries and accession ID included for phylodynamic analysis.

379

Accession ID	Sampling date	Country
hCoV-19/Argentina/C121/2020 EPI_ISL_420600 2020-03-07	07/03/2020	Argentina
hCoV-19/Argentina/C1374/2020 EPI_ISL_420599 2020-03-18	18/03/2020	Argentina
hCoV-19/Argentina/C3013/2020 EPI_ISL_420598 2020-03-22	22/03/2020	Argentina
hCoV-19/Argentina/PAIS_A001/2020 EPI_ISL_430793 2020-03-01	01/03/2020	Argentina
hCoV-19/Argentina/PAIS_A004/2020 EPI_ISL_430796 2020-03-27	27/03/2020	Argentina
hCoV-19/Argentina/PAIS_A005/2020 EPI_ISL_430797 2020-03-27	27/03/2020	Argentina
hCoV-19/Argentina/PAIS_A006/2020 EPI_ISL_430798 2020-03-28	28/03/2020	Argentina
hCoV-19/Argentina/PAIS_A007/2020 EPI_ISL_430799 2020-03-30	30/03/2020	Argentin
hCoV-19/Argentina/PAIS_A009/2020 EPI_ISL_430801 2020-03-31	31/03/2020	Argentina
hCoV-19/Argentina/PAIS_A011/2020 EPI_ISL_430802 2020-03-31	31/03/2020	Argentin
hCoV-19/Argentina/PAIS_A012/2020 EPI_ISL_430803 2020-04-01	01/04/2020	Argentina
hCoV-19/Argentina/PAIS_A013/2020 EPI_ISL_430804 2020-04-01	01/04/2020	Argentina
hCoV-19/Argentina/PAIS_A014/2020 EPI_ISL_430805 2020-04-01	01/04/2020	Argentina
hCoV-19/Argentina/PAIS_A016/2020 EPI_ISL_430807 2020-04-02	02/04/2020	Argentin
hCoV-19/Argentina/PAIS_A017/2020 EPI_ISL_430808 2020-04-03	03/04/2020	Argentin
hCoV-19/Argentina/PAIS_A018/2020 EPI_ISL_430809 2020-04-04	04/04/2020	Argentin
hCoV-19/Argentina/PAIS_A019/2020 EPI_ISL_430810 2020-04-07	07/04/2020	Argentin
hCoV-19/Argentina/PAIS_A020/2020 EPI_ISL_430811 2020-04-11	11/04/2020	Argentin
hCoV-19/Argentina/PAIS_A021/2020 EPI_ISL_430812 2020-04-11	11/04/2020	Argentin
hCoV-19/Argentina/PAIS_A023/2020 EPI_ISL_430814 2020-04-17	17/04/2020	Argentin
hCoV-19/Argentina/PAIS_A024/2020 EPI_ISL_430815 2020-04-18	18/04/2020	Argentin
hCoV-19/Argentina/PAIS_A025/2020 EPI_ISL_430816 2020-04-18	18/04/2020	Argentin
hCoV-19/Argentina/PAIS_A026/2020 EPI_ISL_430817 2020-04-18	18/04/2020	Argentin
hCoV-19/Argentina/PAIS_A027/2020 EPI_ISL_430818 2020-04-19	19/04/2020	Argentin
hCoV-19/Brazil/SPBR-01/2020 EPI_ISL_412964 2020-02-25	25/02/2020	Brazil
hCoV-19/Brazil/SPBR-06/2020 EPI_ISL_414015 2020-02-29	29/02/2020	Brazil
hCoV-19/Brazil/SPBR-09/2020 EPI_ISL_416031 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/RJ-314/2020 EPI_ISL_414045 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/CV42/2020 EPI_ISL_429695 2020-03-20	20/03/2020	Brazil
hCoV-19/Brazil/SPBR-03/2020 EPI_ISL_414014 2020-03-02	02/03/2020	Brazil
hCoV-19/Brazil/SPBR-04/2020 EPI_ISL_414017 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/SPBR-07/2020 EPI_ISL_416028 2020-03-03	03/03/2020	Brazil
hCoV-19/Brazil/RJ-477/2020 EPI_ISL_427300 2020-03-11	11/03/2020	Brazil
hCoV-19/Brazil/RJ-477i/2020 EPI_ISL_427301 2020-03-11	11/03/2020	Brazil
hCoV-19/Brazil/DFBR-0001/2020 EPI_ISL_426580 2020-03-1	13/03/2020	Brazil
hCoV-19/Brazil/SPBR-08/2020 EPI_ISL_416029 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/SPBR-13/2020 EPI_ISL_416035 2020-03-05	05/03/2020	Brazil
hCoV-19/Brazil/BA-510/2020 EPI ISL 427293 2020-03-06	06/03/2020	Brazil

hCoV-19/Brazil/SPBR-12/2020 EPI_ISL_416034 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/DF-615i/2020 EPI_ISL_427294 2020-03-13	13/03/2020	Brazil
hCoV-19/Brazil/DF-862/2020 EPI_ISL_427297 2020-03-23	23/03/2020	Brazil
hCoV-19/Brazil/DF-891/2020 EPI_ISL_427298 2020-03-22	22/03/2020	Brazil
hCoV-19/Brazil/RJ-763/2020 EPI_ISL_427302 2020-03-20	20/03/2020	Brazil
hCoV-19/Brazil/DF-861/2020 EPI_ISL_427296 2020-03-23	23/03/2020	Brazil
hCoV-19/Brazil/RJ-818/2020 EPI_ISL_427303 2020-03-25	25/03/2020	Brazil
hCoV-19/Brazil/RJ-872/2020 EPI_ISL_427304 2020-03-26	26/03/2020	Brazil
hCoV-19/Brazil/AL-837/2020 EPI_ISL_427292 2020-03-18	18/03/2020	Brazil
hCoV-19/Brazil/CV16/2020 EPI_ISL_429676 2020-03-16	16/03/2020	Brazil
hCoV-19/Brazil/SC-769/2020 EPI_ISL_427306 2020-03-10	10/03/2020	Brazil
hCoV-19/Brazil/CV4/2020 EPI_ISL_429667 2020-03-09	09/03/2020	Brazil
hCoV-19/Brazil/CV6/2020 EPI_ISL_429669 2020-03-13	13/03/2020	Brazil
hCoV-19/Brazil/CV21/2020 EPI_ISL_429681 2020-03-16	16/03/2020	Brazil
hCoV-19/Brazil/CV32/2020 EPI_ISL_429688 2020-03-17	17/03/2020	Brazil
hCoV-19/Brazil/CV31/2020 EPI_ISL_429687 2020-03-17	17/03/2020	Brazil
hCoV-19/Brazil/BA-312/2020 EPI_ISL_415105 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/SPBR-02/2020 EPI_ISL_413016 2020-02-28	28/02/2020	Brazil
hCoV-19/Brazil/SPBR-10/2020 EPI_ISL_416032 2020-03-04	04/03/2020	Brazil
hCoV-19/Brazil/ES-225/2020 EPI_ISL_415128 2020-02-29	29/02/2020	Brazil
hCoV-19/Brazil/SC-766/2020 EPI_ISL_427305 2020-03-10	10/03/2020	Brazil
hCoV-19/Brazil/SPBR-11/2020 EPI_ISL_416033 2020-03-03	03/03/2020	Brazil
hCoV-19/Brazil/RJ-352/2020 EPI_ISL_427299 2020-03-05	05/03/2020	Brazil
hCoV-19/Brazil/AMBR-02/2020 EPI_ISL_417034 2020-03-16	16/03/2020	Brazil
hCoV-19/Chile/Santiago-2/2020 EPI_ISL_414580 2020-03-05	05/03/2020	Chile
hCoV-19/Chile/Talca-1/2020 EPI_ISL_414577 2020-03-02	02/03/2020	Chile
hCoV-19/Chile/Talca-2/2020 EPI_ISL_414578 2020-03-04	04/03/2020	Chile
hCoV-19/Chile/Santiago-1/2020 EPI_ISL_414579 2020-03-03	03/03/2020	Chile
hCoV-19/Chile/Santiago_op2d1/2020 EPI_ISL_415658 2020-03-06	06/03/2020	Chile
hCoV-19/Chile/Santiago_op3d1/2020 EPI_ISL_415660 2020-03-07	07/03/2020	Chile
hCoV-19/Chile/Santiago_op4d1/2020 EPI_ISL_415661 2020-03-08	08/03/2020	Chile
hCoV-19/Colombia/Antioquia79256/2020 EPI_ISL_417924 2020-03-11	11/03/2020	Colombia
hCoV-19/Costa Rica/06/2020 EPI_ISL_434539 2020-03-25	25/03/2020	Costa Rica
hCoV-19/Costa Rica/02/2020 EPI_ISL_434535 2020-03-16	16/03/2020	Costa Rica
hCoV-19/Costa Rica/04/2020 EPI_ISL_434540 2020-03-18	18/03/2020	Costa Rica
hCoV-19/Costa Rica/05/2020 EPI_ISL_434538 2020-03-20	20/03/2020	Costa Rica
hCoV-19/Costa Rica/01/2020 EPI_ISL_434533 2020-03-16	16/03/2020	Costa Rica
hCoV-19/Peru/010/2020 EPI ISL 415787 2020-03-10	10/03/2020	Peru